27144-84-9

Basic information

• Product Name: 2-[4-(4-fluorophenyl)piperazin-1-yl]ethanamine
• Synonyms: 2-[4-(4-fluorophenyl)piperazin-1-yl]ethanamine;2-[4-(4-FLUORO-PHENYL)-PIPERAZIN-1-YL]-ETHYLAMINE;OTAVA-BB 7020690397
• CAS NO: 27144-84-9
• Molecular Formula: C₁₂H₁₈FN₃
• Molecular Weight: 223.29
• Mol File: 27144-84-9.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 138-142 °C(Press: 0.05 Torr)
• Appearance: /
• Density: 1.126±0.06 g/cm3(Predicted)
• PKA: 10.11±0.10(Predicted)
• CAS DataBase Reference: 2-[4-(4-fluorophenyl)piperazin-1-yl]ethanamine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[4-(4-fluorophenyl)piperazin-1-yl]ethanamine(27144-84-9)
• EPA Substance Registry System: 2-[4-(4-fluorophenyl)piperazin-1-yl]ethanamine(27144-84-9)

Safety Data

• Hazardous Substances Data: 27144-84-9(Hazardous Substances Data)

Usage

Chemical Class

Substituted phenethylamine

Properties

Psychoactive: Exhibits psychoactive effects on the central nervous system.
Stimulant: Possesses stimulant properties, similar to amphetamine derivatives.
Designer Drug: Classified as a designer drug due to its synthetic nature and psychoactive effects.

Effects

Increased Energy: Stimulates the central nervous system, resulting in heightened energy levels.
Euphoria: Induces feelings of euphoria, typical of stimulant drugs.
Heightened Perception: Enhances sensory perception, leading to altered sensory experiences.

Health Risks

Toxicity: Poses potential toxic effects on the central nervous system.
Addictiveness: Known to be addictive, leading to dependence and withdrawal symptoms upon discontinuation.

Regulatory Status

Not Approved for Medical Use: Not sanctioned for medical purposes due to its psychoactive and harmful effects.
Controlled Substance: Classified as a controlled substance in many countries due to its abuse potential and associated health risks.

Upstream product

• 2252-63-3 1-(4-Fluorophenyl)piperazine 

Downstream Products

• 1608157-04-5 N⁵-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazine-5,7-diamine 
• 1049369-34-7 N-{2-[4-(4-fluorophenyl)piperazin-1-yl]ethyl}-2-naphthalenecarboxamide 
• 1211407-58-7 N-{2-[4-(4-fluorophenyl)piperazin-1-yl]ethyl}-2-quinoxaline carboxamide 
• 1221290-88-5 N-{2-[4-(4-fluorophenyl)piperazin-1-yl]ethyl}-3-quinoline carboxamide 
• 1221290-76-1 N-{2-[4-(4-fluorophenyl)piperazin-1-yl]ethyl}-2-quinoline carboxamide 
• 697287-59-5 {2-[4-(4-fluoro-phenyl)-piperazin-1-yl]-ethyl}-[3-(2-methoxy-phenyl)-isoxazol-5-ylmethyl]-amine 
• 1240266-49-2 C₂₅H₃₁FN₄O*ClH 

Relevant articles and documents

Binding kinetics of ZM241385 derivatives at the human adenosine A 2A receptor

Classical drug design and development rely mostly on affinity- or potency-driven structure-activity relationships (SAR). Thus far, a given compound's binding kinetics have been largely ignored, the importance of which is now being increasingly recognized. In the present study, we performed an extensive structure-kinetics relationship (SKR) study in addition to a traditional SAR analysis at the adenosine A2A receptor (A 2AR). The ensemble of 24 A2AR compounds, all triazolotriazine derivatives resembling the prototypic antagonist ZM241385 (4-(2-((7-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)amino) ethyl)phenol), displayed only minor differences in affinity, although they varied substantially in their dissociation rates from the receptor. We believe that such a combination of SKR and SAR analyses, as we have done with the A 2AR, will have general importance for the superfamily of G protein-coupled receptors, as it can serve as a new strategy to tailor the interaction between ligand and receptor. Above and beyond: Insight into the binding kinetics of ZM241385 derivatives at the human adenosine A2A receptor has provided additional information beyond a traditional structure-activity relationship (SAR) analysis. The strategy, combining a structure-kinetics relationship investigation and SAR, can serve as an important tool for more directed medicinal chemistry efforts in the future.

3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES

The invention relates to 3-heterocyclyl indolyl compounds capable of inhibiting the interaction between p53, or variants thereof, and MDM2 and/or MDM4, or variants thereof, respectively, said compounds having the formula (I) wherein R1, R2, R3, R4, RA, Y and Y are as defined in the specification. Due to their activity, the compounds are useful in the treatment of various disorders and diseases mediated by the activity of MDM2 and/or MDM4, or variants thereof, such as inflammatory or proliferative diseases or in the protection of cells.